This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?

Cormorant Asset Management purchased 2,361,260 shares of MoonLake Immunotherapeutics (MLTX) in Q4 — an estimated $27.86M trade — lifting its quarter-end holding to 4,355,433 shares valued at $57.40M (2.65% of its reportable U.S. equities). MLTX was trading at $17.52 on 2026-02-17, down ~60% Y/Y and after a near-90% one-day drop in September; quarter activity increased the position value by $43.11M reflecting both buys and price movement. MoonLake is a clinical-stage biotech with TTM net loss of $227.3M, Q4 R&D of $56M, admin $9.2M and ~$394M cash runway into H2 next year — the buy appears to be a value/turnaround play on ongoing clinical progress rather than on positive near-term fundamentals.

Analysis

Cormorant’s fourth-quarter accumulation is best read as a concentrated, event-driven value bet: they increased ownership after a ~90% drawdown and ahead of additional clinical readouts/indication expansion, effectively buying asymmetric optionality (low current equity value vs high binary upside if sonelokimab re-rates). The trade amplifies second-order M&A optionality — a successful program would make MoonLake an attractive tuck-in for large immunology players looking for differentiated nanobody assets, meaning upside could be compressed into a short window around positive readouts or licensing talks.

Primary risks are conventional biotech: binary clinical failure, and near-term dilution given cash runway that only extends into H2-2026; that creates a cliff where a small raise can erase current equity value, so timing matters more than direction. Market technicals also matter — large insider/hedge fund positions combined with low float can produce volatile squeezes on good news and rapid sell-offs on financing rumors, increasing tail volatility for option strategies.

From a portfolio construction standpoint, this is a classic asymmetric trade: low probability of large success vs high probability of partial clinical setbacks. The appropriate sizing is tactical (fractions of a percent of AUM) and structured (derivative overlays or spreads) rather than a straight, sizable long. Monitor three near-term inputs: 1) pre-specified Ph3/indication readout windows over next 6–18 months, 2) cash runway / financing cadence into H2-2026, and 3) short interest/float dynamics that will govern intraday gamma on any news.

Key Decisions for Investors

• Tactical long equity (MLTX): establish a 0.25–0.5% AUM position around the current mid-teens price ($17 ±10%). Take profits incrementally on any 30–50% pop; hard stop-loss at -40% from entry (roughly $10) to limit capital at risk given dilution cliff into H2-2026.
• Event-driven call spread (MLTX): buy Jan 2027 $20 call and sell Jan 2027 $40 call (or nearest strikes) sized to 0.1–0.3% AUM. This synthetic limits downside to premium paid while capturing ~2x upside if the asset re-rates or M&A occurs within 12–22 months.
• Hedge the financing cliff: if holding equity, buy 6–9 month puts ~30% OTM to cap downside around expected cash-runway horizon (protects against dilution-driven wipeout). Alternatively, pair long MLTX with a small short position in IBB (or another broad biotech ETF) to isolate company-specific alpha vs sector moves during readouts.
• Pre-announce catalyst sizing rule: increase exposure to 0.5–1.0% AUM only after one of the following — a clear positive Ph3 partial readout, a successful mid-stage binary endpoint in a new indication, or a licensing/M&A rumor confirmed by a material term sheet — and then take 50% off within 2–6 trading days of a >50% price move to de-risk gamma.